SCIENCE@home

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

A. Tolcher,L. Appleman,G. Shapiro,A. Mita,F. Cihon,A. Mazzu,P. Sundaresan

Published 2010 in Cancer Chemotherapy and Pharmacology

ABSTRACT

PurposeTo characterize the cardiovascular profile of sorafenib, a multitargeted kinase inhibitor, in patients with advanced cancer.MethodsFifty-three patients with advanced cancer received oral sorafenib 400 mg bid in continuous 28-day cycles in this open-label study. Left ventricular ejection fraction (LVEF) was evaluated using multigated acquisition scanning at baseline and after 2 and 4 cycles of sorafenib. QT/QTc interval on the electrocardiograph (ECG) was measured in triplicate with a Holter 12-lead ECG at baseline and after 1 cycle of sorafenib. Heart rate (HR) and blood pressure (BP) were obtained in duplicate at baseline and after 1 and 4 cycles of sorafenib. Plasma pharmacokinetic data were obtained for sorafenib and its 3 main metabolites after 1 and 4 cycles of sorafenib.ResultsLVEF (SD) mean change from baseline was −0.8 (±8.6) LVEF(%) after 2 cycles (n = 31) and −1.2 (±7.8) LVEF(%) after 4 cycles of sorafenib (n = 24). The QT/QTc mean changes from baseline observed at maximum sorafenib concentrations (tmax) after 1 cycle (n = 31) were small (QTcB: 4.2 ms; QTcF: 9.0 ms). Mean changes observed after 1 cycle in BP (n = 31) and HR (n = 30) at maximum sorafenib concentrations (tmax) were moderate (up to 11.7 mm Hg and −6.6 bpm, respectively). No correlation was found between the AUC and Cmax of sorafenib and its main metabolites and any cardiovascular parameters.ConclusionsThe effects of sorafenib on changes in QT/QTc interval on the ECG, LVEF, BP, and HR were modest and unlikely to be of clinical significance in the setting of advanced cancer treatment.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-51 of 51 references · Page 1 of 1

CITED BY

Showing 1-72 of 72 citing papers · Page 1 of 1